Ting-Chuan Lee Biography and Net Worth

Director of Ainos


Ms. Lee has served as a Director of the Company since April 2021. She is also a manager at the CEO office. She has served as the chairperson of AI Nose Corporation since March 2016, and as a member of the board of director of Taiwan Carbon Nano Technology Corporation (TCNT)since July 2012. Ms. Lee holds a master’s degree of science from National Taiwan University.

What is Ting-Chuan Lee's net worth?

The estimated net worth of Ting-Chuan Lee is at least $1.04 million as of May 26th, 2026. Ms. Lee owns 807,417 shares of Ainos stock worth more than $1,041,568 as of October 7th. This net worth estimate does not reflect any other investments that Ms. Lee may own. Learn More about Ting-Chuan Lee's net worth.

How do I contact Ting-Chuan Lee?

The corporate mailing address for Ms. Lee and other Ainos executives is 3050 Post Oak Blvd,, Suite 510-t80, Houston, TX, 77056. Ainos can also be reached via phone at (281) 898-6586 and via email at [email protected]. Learn More on Ting-Chuan Lee's contact information.

Has Ting-Chuan Lee been buying or selling shares of Ainos?

Ting-Chuan Lee has not been actively trading shares of Ainos in the last ninety days. Most recently, Ting-Chuan Lee sold 109,988 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $1.90, for a transaction totalling $208,977.20. Following the completion of the sale, the director now directly owns 807,417 shares of the company's stock, valued at $1,534,092.30. Learn More on Ting-Chuan Lee's trading history.

Who are Ainos' active insiders?

Ainos' insider roster includes Ting-Chuan Lee (Director), and Chun-Jung Tsai (Director). Learn More on Ainos' active insiders.

Are insiders buying or selling shares of Ainos?

During the last year, Ainos insiders bought shares 5 times. They purchased a total of 7,800 shares worth more than $15,946.00. During the last year, insiders at the sold shares 7 times. They sold a total of 227,069 shares worth more than $461,398.62. The most recent insider tranaction occured on June, 5th when Director Yao-Chung Chiang bought 3,500 shares worth more than $7,175.00. Insiders at Ainos own 9.8% of the company. Learn More about insider trades at Ainos.

Information on this page was last updated on 6/5/2026.

Ting-Chuan Lee Insider Trading History at Ainos

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2026Sell109,988$1.90$208,977.20807,417View SEC Filing Icon  
6/25/2025Sell578$2.55$1,473.90285,707View SEC Filing Icon  
4/26/2023Buy61,157$0.79$48,314.0361,157View SEC Filing Icon  
See Full Table

Ting-Chuan Lee Buying and Selling Activity at Ainos

This chart shows Ting-Chuan Lee's buying and selling at Ainos by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ainos Company Overview

Ainos logo
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Read More

Today's Range

Now: $1.24
Low: $1.23
High: $1.28

50 Day Range

MA: $1.42
Low: $1.24
High: $1.60

2 Week Range

Now: $1.24
Low: $1.20
High: $4.44

Volume

16,521 shs

Average Volume

387,915 shs

Market Capitalization

$9.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.47